Do GLP-1 medicines increase suicidal thoughts? What regulators found

What the source reports

European regulators began reviewing a possible safety signal in July 2023 after reports of suicidal thoughts and self-injury in people using liraglutide and semaglutide. A safety signal means that new information deserves investigation; it does not establish that a medicine caused the reported event.

The European Medicines Agency's Pharmacovigilance Risk Assessment Committee examined non-clinical studies, clinical trials, post-marketing reports and electronic health-record studies. In April 2024, it concluded that the available evidence did not support a causal association between GLP-1 receptor agonists and suicidal or self-injurious thoughts or actions.

The EMA review covered dulaglutide, exenatide, liraglutide, lixisenatide and semaglutide. The committee decided that no update to European product information was warranted, while requiring manufacturers to continue monitoring new evidence through routine pharmacovigilance.

What the UK review found

The UK Medicines and Healthcare products Regulatory Agency reached a similar conclusion in September 2024. After reviewing UK post-marketing data alongside the European assessment, the MHRA said the evidence did not establish a causal relationship with suicide, suicidal ideation, self-injury or depression.

The MHRA therefore did not require a product-information update. Its current public guidance continues to state that the available data does not support a causal association, while also saying that severe psychiatric reactions remain under safety monitoring and that new data will be assessed as it emerges.

The FDA's larger 2026 analysis

The US Food and Drug Administration issued a more extensive update in January 2026. Its meta-analysis combined 91 placebo-controlled GLP-1 medicine trials involving 107,910 participants: 60,338 received a GLP-1 medicine and 47,572 received placebo.

The FDA reported no increased risk of suicidal ideation or behaviour in that analysis. It also found no increased risk for the other psychiatric events it examined, including anxiety, depression, irritability and psychosis.

A separate FDA Sentinel study compared 1,161,983 new users of GLP-1 medicines with 1,081,155 new users of SGLT2 inhibitors among people with type 2 diabetes. After adjustment for measured baseline differences, the study did not find an increased risk of intentional self-harm, including in the subgroup with both type 2 diabetes and obesity.

Based on the totality of clinical-trial, post-marketing and observational evidence, the FDA requested removal of suicidal-ideation and behaviour warnings from the US prescribing information for Saxenda, Wegovy and Zepbound. Those warnings had been included partly because similar language appeared on labels for older weight-management medicines, rather than because a GLP-1-specific causal link had been established.

What 'no increased risk identified' means

The regulatory conclusion is about comparative risk across large groups. The available evidence does not show that people using these medicines experience suicidal thoughts or behaviour more often because of the medicine than the relevant comparison groups.

It is not a promise that no person will ever experience a serious change in mood during treatment. Population studies estimate patterns across many people; they cannot explain every individual's timing, circumstances or combination of health conditions, other medicines and life events.

A suspected adverse-event report records something that happened after a medicine was used. The report matters because it can contribute to safety-signal detection, but timing alone cannot show whether the medicine caused the event. Regulators assess patterns across reports together with trials, comparison groups and other evidence.

Why the individual experience still matters

Someone who develops new or worsening depression, suicidal thoughts or an unusual change in mood or behaviour is experiencing something important, regardless of whether a medicine is eventually judged to be the cause. A reassuring population-level result should not be used to dismiss or minimise that person's account.

Prompt contact with a prescriber, GP or mental-health professional allows the full situation to be assessed, including when symptoms began, recent dose or treatment changes, other medicines, physical health, sleep, alcohol or substance use, and events in the person's life. The purpose is to understand the individual and provide support, not to assume either that the medicine caused the change or that it could not have contributed.

If someone feels unable to keep themselves safe, has acted on suicidal thoughts or is in immediate danger, seek emergency help now through local emergency services or the nearest emergency department. This article cannot assess an individual crisis.

Reporting a suspected reaction in the UK

Patients, relatives and healthcare professionals can report a suspected medicine reaction through the MHRA Yellow Card scheme even when they are uncertain about causation. Reports help regulators look for patterns that may not have been visible in trials.

Submitting a Yellow Card does not mean that the medicine caused the event, and the number of reports cannot be used on its own to calculate how often an event occurs. The report becomes one part of the wider evidence regulators monitor.

What remains uncertain

No observational study can remove every possible source of confounding, and even large trials have limited ability to characterise extremely rare or highly individual events. Different medicines, indications and patient groups also need continued surveillance as use expands.

However, uncertainty should be described in proportion to the evidence. The current regulatory record is not simply an absence of proof: multiple reviews, a 91-trial FDA meta-analysis and a study involving more than 2.2 million medicine users did not identify an increased risk.

The most accurate conclusion today is therefore two-part: regulators have not found evidence that GLP-1 medicines increase suicidal thoughts or behaviour, and every new or worsening mental-health symptom should still be taken seriously at the individual level.